Rates of Serious Infection Events Similar With Upadacitinib, Adalimumab in Rheumatoid Arthritis
In study data presented at the 2019 ACR Annual Meeting, researchers evaluated the overall safety of upadacitinib as monotherapy and combination therapy with background disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis.
